Past Quarter and this quarter there have been huge number of alliances and mega deals in oncology segment, in rough terms the total comes to around 3 to 4 Billion. What I have observed that the top 10 mega pharma companies are becoming the major players by acquiring or funding smaller companies from drug development to clinical trials in oncology segment.
There are quite many challenges in oncology trials which I will capture later in some other article, so now a days bigger pharma companies are collaborating to incur the cost equally, for example Merck and Astrazeneca as per today's 1st June news headlines are collaborating for Merck's MK-2206 and AstraZeneca's AZD6244, both of which are still in very early development.
There are quite many challenges in oncology trials which I will capture later in some other article, so now a days bigger pharma companies are collaborating to incur the cost equally, for example Merck and Astrazeneca as per today's 1st June news headlines are collaborating for Merck's MK-2206 and AstraZeneca's AZD6244, both of which are still in very early development.
No comments:
Post a Comment